Pune, India

Sonaraj Bholenath Jangam

This inventor holds 1 USPTO granted patent. Top assignee: Lupin, Inc.. Active years: 2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sonaraj Bholenath Jangam. Retrieved from https://idiyas.com/inventor/sonaraj-bholenath-jangam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sonaraj Bholenath Jangam: Innovator in Pharmaceutical Processes

Introduction

Sonaraj Bholenath Jangam is a notable inventor based in Pune, India. He has made significant contributions to the field of pharmaceuticals, particularly in the preparation of polymorphic forms of drugs. His work is characterized by a commitment to innovation and excellence in research.

Latest Patents

Sonaraj holds a patent for a process for the preparation of the polymorphic form of Mirabegron. This invention is directed towards the preparation of the α-form crystal of Mirabegron, which is a compound used in the treatment of overactive bladder. The patent showcases his expertise in developing efficient methods for drug formulation.

Career Highlights

Sonaraj is currently employed at Lupin, Inc., a leading global pharmaceutical company. His role involves extensive research and development, focusing on improving drug formulations and processes. His dedication to advancing pharmaceutical science has earned him recognition in the industry.

Collaborations

Some of his notable coworkers include Girij Pal Singh and Dhananjai Shrivastava. Together, they contribute to innovative projects that aim to enhance the efficacy and safety of pharmaceutical products.

Conclusion

Sonaraj Bholenath Jangam is a distinguished inventor whose work in the pharmaceutical industry exemplifies innovation and dedication. His contributions, particularly in the preparation of Mirabegron, highlight the importance of research in developing effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…